

## ABSTRACT 2023

A. Rosat, B. Terziroli Beretta-Piccoli, L. D. Hoessly, S. Stampf, M. Koller, N. Goossens, M. Fraga, A. Berzigotti, N. Semmo, B. Müllhaupt, D. Semela, M. Heim, S. Brunner, M. Pascual, D. Moradpour, J. Vionnet and the Swiss Transplant Cohort Study, Liver transplant recipients with autoimmune hepatitis as initial indication in the Swiss Transplant Cohort Study have a higher risk of graft loss and complications, Abstract accepted as poster at the EASL Congress, Vienna, Austria on 21-24.6.2023.

Barda B, Di Mari B, Baserga A, Robatto A, Magenta L, Messina P, Bissig M, Cerny A. Evaluation of the efficacy of Methylene Blue administration in SARS-CoV-2- affected patients: a proof of concept phase 2, randomized, placebo- controlled, single blind clinical trial. Abstract submitted to ECCMID 2023 33rd European Congress of Clinical Microbiology and Infectious Diseases (Copenhagen, Denmark on 15 - 18 April 2023).

Tseligka E., Conzelmann S., Cerny A., Cerny T., Cerny E., Tapparel C., Negro F., Clément S., Methylene Blue shows an antiviral activity against hepatitis D virus in vitro, Abstract accepted as poster at the Joint Annual Meeting Swiss Society for Infectious Diseases SSI and Swiss Society for Hospital Hygiene SSHH, Zürich, Switzerland on September 13-15, 2023

Malino D., Codoni G., Kirchner T., Engel B., Maria Villamil A. M., Efe C., Stättermayer A. F., Weltzsch J. P., Sebode M., Bernsmeier C., Lleo A., Gevers T. JG, Kupčinskis L., Castiella A., Pinazo J., De Martin E., Bobis I., Sandahl T. M., Pedica F., Invernizzi F., Del Poggio P., Bruns T., Kolev M., Semmo N., Bessone F., Giguët B., Poggi G., Ueno M., Jang H., Elpek G. O., Soylu N. K., Cerny A., Wedemeyer H., Vergani D., Mieli-Vergani G., Lucena M.I., Andrade R.J., Zen Y., Taubert R., Terziroli Beretta-Piccoli B., Acute liver injury after COVID-19 vaccines: risk factors for prolonged, immunosuppression-dependent course. ation in an ERN/IAIHG cohort: autoimmune hepatitis versus drug-induced autoimmune-like hepatitis, Abstract accepted as oral presentation at the 4th Swiss Autoimmune Liver Disease Meeting, Lugano, September 22, 2023.

Bregenzer A. Bruggmann P, Castro E, Della Santa P, Hensel-Koch K, Moriggia A, Thurnheer MC, Scheidegger C Occurrence and outcome of hepatitis c reinfections in opioid agonist therapy patients of the SAMMSU Cohort.; Abstract accepted as poster at the 11th International Conference on Health and Hepatitis in Substance Users (INHSU 2023), Geneva, Switzerland on 17 - 20 Oct 2023.

Bregenzer A, Bruggmann P, Castro E, Della Santa P, Hensel-Koch K, Moriggia A, Thurnheer MC, Scheidegger C Current prevalence of and risk factors for liver cirrhosis in opioid agonist therapy patients of the SAMMSU Cohort after 5 years of unrestricted DAA access.; Abstract accepted as poster at the 11th International Conference on Health and Hepatitis in Substance Users (INHSU 2023), Geneva, Switzerland on 17 - 20 Oct 2023.

Kowdley K. V, Bowlus C. L, Levy C, Akarca U.S, Reis Alvares-da-Silva M, Andreone P, Arrese M, M.D, et al, for the ELATIVE Study Investigators, Efficacy and Safety of Elafibranor in Primary Biliary Cholangitis, Published November 13, 2023, N Engl J Med 2024;390:795-805, DOI: 10.1056/NEJMoa2306185, VOL. 390 NO. 9